MiniMed Group's stock fell 5.00% during intraday trading on Friday, as the newly public company experienced significant selling pressure following its market debut.
The diabetes business subsidiary of Medtronic priced its initial public offering at $20 per share, but was indicated to open at $19, reflecting investor skepticism about the valuation. The stock began trading on the Nasdaq Global Select Market, with the opening discount contributing to the downward price movement.
Market participants reacted to the discrepancy between the IPO pricing and the indicated opening price, leading to the sharp decline in early trading activity.